The treatment strategy of bladder cancer has evolved not only through the traditional modalities of surgery and chemotherapy but also by immunotherapy over the past several decades.Immunotherapies such as intravesical...The treatment strategy of bladder cancer has evolved not only through the traditional modalities of surgery and chemotherapy but also by immunotherapy over the past several decades.Immunotherapies such as intravesical Bacillus Calmette-Guérin(BCG)vaccines and immune checkpoint blockades(ICBs)are sometimes used for treating patients with bladder cancer,especially those who develop resistance to conventional first-line treatments such as surgery and chemotherapy.Unfortunately,it is a limited number of individuals that see clinical benefits from this approach,and complicating matters more is that many of these patients suffer severe immune-related adverse events(ir AEs).If current momentum continues to result in improved response rates and managed ir AEs,immunotherapy could be poised to revolutionize the landscape of urothelial carcinoma therapeutics.展开更多
基金supported by the National Key Research and Development Program of China(2017YTA0105900)。
文摘The treatment strategy of bladder cancer has evolved not only through the traditional modalities of surgery and chemotherapy but also by immunotherapy over the past several decades.Immunotherapies such as intravesical Bacillus Calmette-Guérin(BCG)vaccines and immune checkpoint blockades(ICBs)are sometimes used for treating patients with bladder cancer,especially those who develop resistance to conventional first-line treatments such as surgery and chemotherapy.Unfortunately,it is a limited number of individuals that see clinical benefits from this approach,and complicating matters more is that many of these patients suffer severe immune-related adverse events(ir AEs).If current momentum continues to result in improved response rates and managed ir AEs,immunotherapy could be poised to revolutionize the landscape of urothelial carcinoma therapeutics.
